MedPath

A Study in the Treatment of Acute Mania

Phase 4
Terminated
Conditions
Bipolar Disorder
Interventions
Registration Number
NCT00767715
Lead Sponsor
Eli Lilly and Company
Brief Summary

The purpose of this study is to test the efficacy and total costs of olanzapine versus commonly used conventional antipsychotics in Sweden.

Detailed Description

The primary objective is to show that the efficacy of olanzapine is non-inferior to the conventional antipsychotics haloperidol or zuclopentixol in the treatment of an acute manic or mixed episode of bipolar disorder. Efficacy is defined as time to remission, as measured by the total scores of the Young Mania Rating Scale (Y-MRS), MADRS-S, and Clinical Global Impression - Bipolar (CGI-BP). Time from baseline to remission is defined as the primary efficacy measure. Remission is defined as a Y-MRS score \<=12 AND a MADRS-S score \<=12 AND CGI-BP = 1 or 2.

Secondary efficacy assessments will include time from baseline to

* Response, as defined as a reduction of Y-MRS score greater than or equal to 50% compared to baseline

* Relapse of mania, as defined as a Y-MRS score \>= 16 AND CGI-BP \>2 after having met the criteria for remission

* Switch into depression, as defined as a MADRS-S score \>=17 AND fulfilled criteria for Major Depression as self-assessed by DSRS.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
11
Inclusion Criteria
  • Diagnosis of bipolar I disorder and currently display an acute manic or mixed episode (with or without psychotic features)
  • Patients must have a Y-MRS total score of greater or equal to 20 at visit 2
  • Patients must have experienced at least one manic or mixed episode prior to study enrollment
  • Female of childbearing potential must be using a medically accepted means of contraception, or practice sexual abstinence
  • Each patient must have a level of understanding sufficient to communicate intelligently with study personnel
  • Patients must be considered reliable
  • Each patient must understand the nature of the study and signed informed consent
Read More
Exclusion Criteria
  • Female patients who are pregnant or lactating
  • Serious, unstable illnesses such that hospitalization for the disease is anticipated within 3 month or death is anticipated within 3 years
  • Uncorrected hypothyroidism or hyperthyroidism
  • Narrow-angle glaucoma
  • History of allergic reactions or intolerance to study medications
  • DSM-IV substance dependence within the past 30 days at the judgement of the investigator
  • Judged clinically to be at serious suicidal risk
  • Treatment with an injectable depot neuroleptic within less than one dosing interval between depot neuroleptic injections prior to visit 2
  • Any patient treated with clozapine within 4 weeks prior to visit 2
  • Subjects who have received treatment with ECT within one month prior to visit 1
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
AolanzapinePatients will be given olanzapine
BhaloperidolPatients will be given either haloperidol or zuclopentixol
BzuclopentixolPatients will be given either haloperidol or zuclopentixol
Primary Outcome Measures
NameTimeMethod
Time to remission by Young Mania Rating Scale, MADRS-S and CGI-BP5 months
Secondary Outcome Measures
NameTimeMethod
Euro Qol instrument5 months
Frequency of and time to relapse into mania by Y-MRS and CGI-BP5 months
Adverse events5 months
Resource utilization Clinical Report Form (RUCRF)5 months
Disability free day assessment (DFDA)5 months
Medical Outcomes Study 36-Item Short Form Health Survey (SF-36)5 months
Time to remission in patients with psychotic features by SCID-I judgement, Y-MRS item 8 and PANSS positive items mean sum5 months
Medication compliance5 months
Response by Y-MRS5 months
Frequency of and time to switch to depression by MADRS-S and DSRS5 months
Drug Attitude Inventory (DAI)5 months

Trial Locations

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

🇸🇪

Danderyd, Sweden

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
🇸🇪Danderyd, Sweden
© Copyright 2025. All Rights Reserved by MedPath